The Bioinnovation Institute (BII) have accepted biotech start-up 2N Pharma into its Creation House program awarding the start-up EUR 1.3 million to develop its first in class treatment for the neurodegenerative disease ALS (amyotrophic lateral sclerosis).
Also called Lou Gehrig or motor neuron disease, ALS is a condition with no known cure.
“We are thrilled to join Creation House where the BII infrastructure, staff and funding will enable us make enormous progress towards our goal of bringing a ground-breaking treatment to ALS patients, giving them hope for a cure for the first time. As a small company, it can be a struggle to reach the network you need. Being a Creation House company opens many doors and we can already see this huge advantage from our early conversations”, said Preben Bruun-Nyzell, CEO of 2N Pharma.
Giles Dudley, Senior Business Developer at BII will be anchoring the start-up and has worked with the team on the milestone plan.